[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594718":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":40,"centralContacts":44,"locations":50,"responsibleParty":66,"collaborators":27,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":27,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":27,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":27,"overallStatus":52,"whyStopped":27,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Poznan University of Medical Sciences","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"PENG + LFCB","ACTIVE_COMPARATOR","U-S guided PENG block - 0.4ml\u002Fkg 0.2% ropivacaine\n\n\\+ U-S guided LFCB - 0.1ml\u002Fkg 0.2% ropivacaine",[13,14],"Drug: Ropivacaine 0.2% for PENG Block","Drug: Ropivacaine 0.2% for LFCB",{"label":16,"type":10,"description":17,"interventionNames":18},"L-ESPB + S-ESPB","U-S guided L-ESPB - 0.25ml\u002Fkg 0.2% ropivacaine\n\n\\+ U-S guided S-ESPB - 0.25ml\u002Fkg 0.2% ropivacaine",[19,20],"Drug: Ropivacaine 0.2% for L-ESPB","Drug: Ropivacaine 0.2% for S-ESPB",[22,28,32,36],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Ropivacaine 0.2% for PENG Block","U-S guided PENG (0.4 mL\u002Fkg) with 0.2% ropivacaine",[9],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"Ropivacaine 0.2% for LFCB","LFCB (0.1 mL\u002Fkg) with 0.2% ropivacaine",[9],{"type":23,"name":33,"description":34,"armGroupLabels":35,"otherNames":27},"Ropivacaine 0.2% for L-ESPB","Lumbar ESPB (0.25ml\u002Fkg) with 0.2% ropivacaine",[16],{"type":23,"name":37,"description":38,"armGroupLabels":39,"otherNames":27},"Ropivacaine 0.2% for S-ESPB","Sacral ESPB (0.25ml\u002Fkg) with 0.2% ropivacaine",[16],[41],{"name":42,"affiliation":5,"role":43},"Malgorzata Reysner, M.D. Ph.D.","PRINCIPAL_INVESTIGATOR",[45],{"name":46,"role":47,"phone":48,"phoneExt":27,"email":49},"Malgorzata Reysner","CONTACT","+48 61 873 83 03","mreysner@ump.edu.pl",[51],{"facility":5,"status":52,"city":53,"state":27,"zip":27,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"RECRUITING","Poznan","Poland","PL",{"type":57,"coordinates":58},"Point",[59,60],16.92993,52.40692,{"lat":60,"lon":59},[63],{"name":64,"role":47,"phone":65,"phoneExt":27,"email":49},"Malgorzata Reysner, MD. Ph.D.","+608762068",{"type":67,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100594718","phase-4-peng-with-lfcb-vs-esp-blocks-for-pediatric-hip-surgery-100594718",false,"NCT07023094","PENG With LFCB vs. ESP Blocks for Pediatric Hip Surgery","Comparison of Analgesic Efficacy of Pericapsular Nerve Group (PENG) Block With Lateral Femoral Cutaneous Nerve Block (LFCB) Versus Lumbar and Sacral Erector Spinae Plane Blocks (L-ESPB and S-ESPB) in Pediatric Hip Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Pediatric patients aged between 2 and 16 years.\n* Scheduled for elective orthopedic hip surgery, including: Osteotomies and Hip reconstruction surgeries\n* ASA (American Society of Anesthesiologists) physical status classification: I-III.\n* Written informed consent obtained from the patient's legal guardian(s).\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to any of the study medications\n* Presence of infection or inflammation at the intended injection site(s) of regional anesthesia.\n* Coagulopathy or bleeding disorders (including patients on anticoagulant therapy) that contraindicate nerve blocks.\n* Neurological disorders or peripheral neuropathies that could influence sensory or motor assessment of the lower limbs.\n* Cognitive impairment or behavioral disorders significantly affecting pain assessment accuracy or cooperation.\n* History of chronic opioid use or known substance abuse.\n* Severe systemic disease or condition compromising patient safety or interfering with study protocol adherence.","ALL","2 Years","16 Years",{"count":79,"type":80},60,"ESTIMATED","INTERVENTIONAL",[83],"PHASE4","This randomized controlled trial (RCT) compares the analgesic effectiveness of two regional anesthesia techniques-Pericapsular Nerve Group (PENG) block combined with Lateral Femoral Cutaneous Nerve Block (LFCB) versus Lumbar and Sacral Erector Spinae Plane Blocks (L-ESPB and S-ESPB)-in pediatric patients undergoing hip surgery.",[86,87,88],"Hip Disease","Hip Dysplasia","Hip Arthropathy","2025-07-08",{"date":91,"type":92},"2025-07-11","ACTUAL",{"date":94,"type":92},"2025-06-16",{"date":96,"type":80},"2026-06-30",{"name":5,"class":6},1]